Biopharma | December 04, 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
